×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
Featured Press Releases
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
ProJenX announces the formation of its Clinical Advisory Board
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Search Form
Search Terms:
Search
Did you mean:
👉active👈 kup kind in
?
No Results Found
No search results could be found for query: 👉acc6.top👈 kup konto Omiai.
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Nuvation Bio unveils new data on IBTROZI™ (taletrectinib) in advanced ROS1-positive non-small cell lung cancer
By
Nuvation Bio
Sep 08
FDA approves Apellis' EMPAVELI® (pegcetacoplan) as the first treatment for patients aged 12 and older with C3G and primary IC-MPGN
By
Apellis Pharmaceuticals, Inc.
Jul 30
AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes
By
AbbVie
Jun 12
July
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe to Our Monthly Newsletter
Subscribe to Pharmaceutical Era’s monthly newsletter,
Pharmaceutical Leaders Digest
®, to receive timely updates from across the pharmaceutical industry.
I agree with the
Terms and conditions
×
and the
Privacy policy
×
Please enable the javascript to submit this form
Subscribe
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand
